Lopina N, Dyagil I, Hamov D, Zhuravlyova L, Dmytrenko I, Lopin D
Cureus. 2018; 10(8):e3136.
PMID: 30345193
PMC: 6188217.
DOI: 10.7759/cureus.3136.
Nacif L, Waisberg D, Pinheiro R, Lima F, Rocha-Santos V, Andraus W
J Med Case Rep. 2018; 12(1):63.
PMID: 29523185
PMC: 5845231.
DOI: 10.1186/s13256-018-1588-0.
Steegmann J, Baccarani M, Breccia M, Casado L, Garcia-Gutierrez V, Hochhaus A
Leukemia. 2016; 30(8):1648-71.
PMID: 27121688
PMC: 4991363.
DOI: 10.1038/leu.2016.104.
Gharwan H, Groninger H
Nat Rev Clin Oncol. 2016; 13(4):209-27.
PMID: 26718105
DOI: 10.1038/nrclinonc.2015.213.
Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N
Ann Gastroenterol. 2014; 25(2):106-118.
PMID: 24713845
PMC: 3959393.
Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia.
Hua J, Iwaki Y, Inoue M, Hagihara M
Int J Hematol. 2013; 98(2):243-6.
PMID: 23649869
DOI: 10.1007/s12185-013-1356-2.
Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.
Shah R, Morganroth J, Shah D
Drug Saf. 2013; 36(7):491-503.
PMID: 23620168
DOI: 10.1007/s40264-013-0048-4.
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.
Mughal T, Schrieber A
Biologics. 2011; 4:315-23.
PMID: 21209726
PMC: 3010822.
DOI: 10.2147/BTT.S5775.
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N
Med Oncol. 2009; 27(3):768-73.
PMID: 19662540
DOI: 10.1007/s12032-009-9284-y.
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).
Henkes M, van der Kuip H, Aulitzky W
Ther Clin Risk Manag. 2008; 4(1):163-87.
PMID: 18728706
PMC: 2503652.
Imatinib-induced fatal acute liver failure.
Ridruejo E, Cacchione R, Villamil A, Marciano S, Gadano A, Mando O
World J Gastroenterol. 2007; 13(48):6608-111.
PMID: 18161937
PMC: 4611306.
DOI: 10.3748/wjg.v13.i48.6608.
Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Arai A, Yan W, Wakabayashi S, Hayashi S, Inazawa J, Miura O
Int J Hematol. 2007; 86(3):233-7.
PMID: 17988989
DOI: 10.1532/IJH97.07032.
Imatinib mesylate (gleevec) hepatotoxicity.
Mindikoglu A, Regev A, Bejarano P, Martinez E, Jeffers L, Schiff E
Dig Dis Sci. 2007; 52(2):598-601.
PMID: 17219077
DOI: 10.1007/s10620-006-9117-1.
Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Ikuta K, Torimoto Y, Jimbo J, Inamura J, Shindo M, Sato K
Int J Hematol. 2005; 82(4):343-6.
PMID: 16298828
DOI: 10.1532/IJH97.05034.
